Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Euthyroid Group · 1 trial · 1 indication
PET/CT was performed before (basal PET) and 24-48 h after rhTSH administration (rhTSH-PET) in 63 patients (52 papillary and 11 follicular thyroid cancers). Images were blindly analyzed by two readers. The proposed treatment plan was prospectively assessed before basal PET, after basal PET, and again after rhTSH-PET.
| Arm | Type | Description |
|---|---|---|
| Euthyroid Group | EXPERIMENTAL | Euthyroid Group: Subjects received rhTSH to prepare for radioiodine therapy. |
| Hypothyroid Group | NO_INTERVENTION | Hypothyroid Group: Thyroid hormone treatment was withheld before radioiodine therapy. |
| Name | Type | Description |
|---|---|---|
| Euthyroid Group | DRUG | Euthyroid Group: Received rhTSH to prepare for radioiodine therapy. |
Inclusion Criteria: * Adults (aged ≥ 18 years) with history of treated well-differentiated epithelial thyroid carcinoma (papillary, follicular or Hurthle cell), for which total or near total thyroidectomy plus postoperative radioiodine remnant ablation with 131-I has either been performed or found ...
Euthyroid Group is an investigational small molecule being studied for use in Thyroid Cancer. It is currently in Phase 2 clinical development, with one completed trial involving 63 participants. The drug is being developed by Sanofi and has not yet been approved for any use.
Sanofi (ticker: SNY) is developing Euthyroid Group. The drug is an investigational small molecule in Phase 2 clinical development for Thyroid Cancer. Sanofi has conducted one completed clinical trial of Euthyroid Group, which enrolled 63 participants.
Euthyroid Group is in Phase 2 clinical development for Thyroid Cancer. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug has completed one Phase 2 trial, and no active trials are currently listed.
Euthyroid Group has one completed clinical trial, NCT00181168, titled 'Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer.' This Phase 2 study enrolled 63 participants in the United States and France, with a minimum age of 18 years. The trial was not blinded and had no treatment control.
Euthyroid Group is not FDA approved. It is an investigational drug in Phase 2 clinical development for Thyroid Cancer. The drug has completed one clinical trial, but it remains under investigation and has not received regulatory approval for any indication.